Literature DB >> 28120571

Filaggrin Mutation in Korean Patients with Atopic Dermatitis.

Hye Rang On1, Sang Eun Lee1, Song Ee Kim1, Won Jin Hong1, Hyun Jung Kim2, Toshifumi Nomura3, Shotaro Suzuki3, Hiroshi Shimizu3, Soo Chan Kim4.   

Abstract

PURPOSE: Atopic dermatitis (AD) is a chronic, relapsing eczematous inflammatory skin disease. Mutations in the filaggrin gene (FLG) are major predisposing factors for AD. Ethnic differences exist between Asian and European populations in the frequency and spectrum of FLG mutations. Moreover, a distinct set of FLG mutations has been reported in Asian populations. The aim of this study was to examine the spectrum of FLG mutations in Koreans with AD. We also investigated the association of FLG mutations and clinical features of AD and compared the Korean FLG landscape with that of other East Asian countries.
MATERIALS AND METHODS: Seventy Korean patients with AD were enrolled in this study. Fourteen FLG mutations previously detected in Korean, Japanese, and Chinese patients were screened by genotyping.
RESULTS: Four FLG null mutations (3321delA, K4022X, S3296X, and S2889X) were identified in eleven patients (15.7%). The most commonly detected mutations in Korean patients with AD were 3321delA (n=6, 9.1%) and K4022X (n=3, 4.5%). FLG mutations were significantly associated with elevated IgE (≥200 KIU/L and/or MAST-CLA >3+, p=0.005), palmar hyperlinearity (p<0.001), and a family history of allergic disease (p=0.021).
CONCLUSION: This study expanded our understanding of the landscape of FLG mutations in Koreans and revealed an association between FLG mutations and AD phenotype.

Entities:  

Keywords:  Atopic dermatitis; Korean; filaggrin mutation

Mesh:

Substances:

Year:  2017        PMID: 28120571      PMCID: PMC5290020          DOI: 10.3349/ymj.2017.58.2.395

Source DB:  PubMed          Journal:  Yonsei Med J        ISSN: 0513-5796            Impact factor:   2.759


INTRODUCTION

Atopic dermatitis (AD) is a chronic and relapsing pruritic inflammatory skin disease, often associated with elevated serum IgE levels and a family history of AD, allergic rhinitis, and asthma.12 The prevalence of AD in industrialized countries has recently increased to 15 to 30% in children and 2 to 10% in adults.3 AD has a complex etiology with genetic, immunological, and environmental aspects. Mutations in the filaggrin gene (FLG) are the most common and significant genetic defects identified to date causing AD, emphasizing the role of skin barrier alterations in AD pathogenesis.1456 FLG was first identified by Dale7 in 1977 as a highly insoluble, histidine-rich protein that was co-purified with keratin intermediate filament proteins in epidermal extracts. FLG monomers have been thought to promote corneocyte compaction by contributing to keratin pattern formation in the lower stratum corneum (SC).4 FLG monomers are proteolyzed into natural moisturizing factors, which are necessary to maintain hydration of the upper SC and acidic pH of the skin surface.1 FLG mutations have been identified as the underlying cause of ichthyosis vulgaris8 (IV; OMIM 146700), which is characterized by dry and scaly skin, palmar and plantar hyperlinearity, and keratosis pilaris.9 Furthermore, FLG mutations have proved to be a major predisposing factor for AD in Europe and Asia.610 Patients with AD who carry FLG mutations have been reported to have more persistent and severe disease, a higher incidence of herpes virus infection, allergic sensitization, and a greater risk of multiple allergies than patients with AD without FLG mutations.15 Some FLG mutations (R501X, R1891X, 3321delA, S1405X, S1515X, W1947X, G2025X, E3070X, Q1701X, Y1767X, S3296X, and K4022X) have been identified in Korea.11121314 This study aimed to examine the spectrum of FLG-null mutations in Koreans with AD to investigate the association between FLG mutations and clinical AD markers and to compare the landscape of Korean FLG mutations with that of other Asian countries.

MATERIALS AND METHODS

Clinical materials

Seventy Korean patients with AD whose parents and all four grandparents were recorded as ethnic Korean were enrolled. Diagnosis of AD was confirmed by experienced dermatologists using AD diagnostic criteria created by Hanifin and Rajka.15 Patients were divided into three groups according to age of onset: early childhood onset (<8 years), late childhood onset (8–18 years), and adult onset (>18 years). AD disease severity was assessed using the SCORing Atopic Dermatitis (SCORAD) index, and patients with AD were grouped into mild (<15 points), moderate (15–40 points), and severe (>40 points) disease gro-ups.16 Peripheral blood samples were analyzed for total serum IgE levels and specific IgE levels for egg, milk, soybean, peanut, fish, wheat, mites (Dermatophagoides pteronyssinus, Dermatophagoides farinae), and cockroach by multiple allergosorbent test chemiluminescent assay (MAST-CLA; Advan-SureTM AlloStation, LG Life Science, Seoul, Korea). Total IgE concentrations ≥200 KIU/L and/or ≥3+ in three categories of the MAST-CLA test were arbitrarily defined as elevated IgE in this study.1718 Associated allergic diseases, including asthma and allergic rhinitis, were determined on the basis of the questionnaire and previous diagnoses by physicians. Patients provided written informed consent, which complied with the principles of the Declaration of Helsinki. This study was approved by the Institutional Review Board (IRB No. 3-2014-0027) of Gangnam Severance Hospital, Seoul.

Mutation analysis

Genomic DNA was extracted from peripheral blood leukocytes with a DNA extraction kit (QIAamp DNA Blood Midi kit, Qiagen, Hilden, Germany). Patients with AD were screened for fourteen FLG mutations that have been identified in Korea, Japan, and China (R501X, 3321delA, S1695X, Q1701X, Q1745X, Y1767X, Q1790X, S2554X, S2889X, S3296X, 3222del4, S1515X, Q2417X, and K4022X) by direct DNA sequencing as described previously.1920

Statistical analysis

Descriptive statistics for quantitative values were expressed as means [±standard deviation (SD)] in accordance with the data distribution. Frequencies and percentages were used to describe categorical variables. We used Fisher's exact test to assess the associations between FLG mutations and AD, as well as AD-associated phenotypes, including age of onset of AD, SCORAD index, allergic AD, family history of AD, and associated allergic diseases like asthma and allergic rhinitis. The strength of associations was estimated by calculating odds ratios and 95% confidence intervals. The level of statistical significance was established at α<0.05. Statistical analyses were performed using SPSS version 19 (SPSS Inc., Chicago, IL, USA).

RESULTS

Clinical features

The clinical characteristics of patients with AD are presented in Table 1. A total of 70 patients were enrolled in this study. The mean age was 19.3 years (range 0 to 63, SD=13.14), and 68.6% of patients were male. Thirteen patients had mild AD, 25 had moderate, and 32 had severe AD, as determined by the SCORAD index. Fifty-seven (81.4%) patients had moderate to severe disease. In the AD cohort, 24.3% of patients had hyperlinear palms.
Table 1

Clinical Characteristics of Korean Patients with AD in This Study

CharacteristicsNumber of patients (%)
Total AD patients70
Mean age (yrs)19.3 (range 0–63)
Sex
 Male48 (68.6)
 Female22 (31.4)
Elevated IgE*44 (62.8)
Hyperlinear palms17 (24.2)
Age of onset (yrs)
 Early childhood (<8)53 (75.7)
 Late childhood (8–18)10 (14.3)
 Adult (>18)7 (10.0)
Family history28 (40.0)
Allergic disease association25 (35.7)
Severity (SCORAD index)
 Mild (<15 points)13 (18.6)
 Moderate (15–40 points)25 (35.7)
 Severe (>40 points)32 (45.7)

AD, atopic dermatitis; SCORAD, SCORing Atopic Dermatitis.

*Total IgE ≥200 KIU/L and/or specific IgE ≥3+, †Allergic disease: allergic rhinitis and/or asthma.

FLG mutations in AD patients

Among the fourteen mutations screened, four, S2889X, S3296X, 3321delA, and K4022X, were identified in our AD patients (Table 2, Fig. 1). Eleven patients had FLG mutations, and all were heterozygous for the mutation. All patients with FLG mutations had moderate to severe AD (Fig. 2). Mutations 3321delA, K4022X, S3296X, and S2889X were carried by six (9.1%), three (4.5%), two (3.0%), and one (1.5%) individuals, respectively. One patient was a heterozygous carrier of two different FLG mutations. This study is the first time S2889X has been identified in Koreans with AD (Fig. 1).
Table 2

Atopic Dermatitis Association Analysis for FLG Null Variants in Korea

GenotypeR501X3321delAY1767XS1695XQ1701XQ1745XQ1790XS2554XS2889XS3296XK4022X3222del4S1515XQ2417X
AA7064707070707070696867707070
Aa06000000123000
aa00000000000000
Total7070707070707070707070707070

FLG, filaggrin gene.

Fig. 1

FLG mutations detected in patients with atopic dermatitis. (A) A heterozygous deletion mutation, 3321delA, in FLG repeat 2 in exon 3 was identified in patient no. 28. (B) Two heterozygous transition mutations, c.8666C→G and c.8667C→A, in patient no. 11 resulted in S2889X. (C) A heterozygous transition mutation, c.9887C→A, in patient no. 66 resulted in S3296X. (D) A heterozygous transition mutation, 14011A→T, in patient no. 40 resulted in nonsense mutation K4022X. FLG, filaggrin gene.

Fig. 2

Clinical features of patients with atopic dermatitis. (A) Palmar hyperlinearity of an atopic dermatitis patient with mutation K4022X. (B) Fine scales and xerosis on the trunk of a patient with mutations S2889X and S3296. (C) Erythematous papules and a patch on the back of a patient with mutation 3321delA.

Associations between FLG mutations and AD characteristics

FLG mutations were significantly associated with elevated IgE, palmar hyperlinearity, and a family history of allergic disease (p<0.05) (Table 3). All patients with FLG mutations had high IgE, and were positive for MAST-CLA or moderate to severe AD. Palmar hyperlinearity was present in eight patients (72.7%) with AD and FLG mutations. Eight patients (72.7%) with FLG mutations had a family history of allergic disease. Age of onset was not significantly associated with FLG mutation. AD severity was not statistically significantly associated with FLG mutation (p=0.115).
Table 3

Clinical Characteristics of Korean Patients with AD and with or without FLG Mutations

CharacteristicAD with FLG mutations (%)AD without FLG mutations (%)p value
Number of patients1159-
Age (range), yrs28 (0–63)18 (0–43)-
Sex
 Male8 (72.7)40 (67.8)-
 Female3 (27.3)19 (32.2)-
Elevated IgE*11 (100)33 (55.9)0.005
Hyperlinear palms8 (72.7)9 (15.3)<0.001
Age of onset (yrs)0.545
 Early childhood (< 8)8 (72.7)45 (76.3)
 Late childhood (8–18)1 (9.1)9 (15.3)
 Adult (>18)2 (18.2)5 (8.5)
Family history of allergic disease8 (72.7)20 (33.4)0.021
Allergic disease association†4 (36.4)21 (35.6)1.000
Severity (SCORAD index)0.115
 Mild (<15 points)0 (0)13 (22.0)
 Moderate (15–40 points)3 (27.3)22 (27.3)
 Severe (>40 points)8 (72.7)24 (40.7)

FLG, filaggrin gene; AD, atopic dermatitis; SCORAD, SCORing Atopic Dermatitis.

*Total IgE ≥200 KIU/L and/or specific IgE ≥3+, †Allergic disease: allergic rhinitis and/or asthma.

Clinical phenotype differences among each FLG mutations are shown in Table 4 and Fig. 3. Although clinical severity and phenotypic expression tended to differ among mutation types, statistical significance was not reached since the number of patients was too small.
Table 4

Clinical Characteristics of Korean Patients with Atopic Dermatitis and with FLG Mutations

FLG mutationPatient numberScorad scoreHyperlinear palmFamily history of allergic diseaseAllergic disease associationIgE (KIU/L)Age of onset (yrs)
3321delA1659YesYesNo37762
2428NoYesNo68.40
2823NoYesNo30.60
3436YesYesYes>1000.08
4854YesYesYes>1000.05
6350YesYesYes41191
K4022X557NoNoYes>1000.00
3341YesNoNo1675
4069YesNoNo>1000.031
S3296X1168YesYesNo4057
6749YesYesNo21240
S2889X1148YesYesNo4057

FLG, filaggrin gene.

Fig. 3

Clinical phenotype difference among each FLG mutations. (A) SCORAD index. (B) Age of onset. (C) IgE level. FLG, filaggrin gene; SCORAD, SCORing Atopic Dermatitis.

DISCUSSION

Since two FLG mutations, R501X and 2282del4, were identified in Europeans with AD, many replication studies have reported the prevalence and frequency of mutations in the FLG in individuals with AD.910 New FLG mutations associated with AD have been widely reported in European and non-European cohorts. Previous reports have also shown variations in FLG mutations among individuals with AD in different ethnic groups. The most prevalent FLG mutations are R501X and 2282del4 and have been reported to be present in up to 48% of Europeans with AD.15 The mutation landscape in Asians with AD cohorts has been reported to vary, and the frequency was reported to be much lower than that in Europeans. Although many European countries have a similar FLG mutation landscape, Asian countries have been reported to have distinct FLG mutation landscapes. Among the Asian-specific FLG null mutations identified in Japan, China, Taiwan, and Singapore, only 3321delA was common. In a Japanese AD cohort, the S2554X and S2889X mutations were the most prevalent, followed by 3321delA and S3296X.2122 3321delA and K4671X were the most common FLG mutations in an AD cohort in China.2324 Hsu, et al.25 identified three FLG mutations, 3321delA, Q2417X, and E1795X, in Taiwanese families with ichthyosis vulgaris. The 3321delA mutation was the most prevalent FLG mutation in Singapore.26 In this study, fourteen FLG mutations, R501X, 3321delA, S1695X, Q1701X, Q1745X, Y1767X, Q1790X, S2554X, S2889X, S3296X, 3222del4, S1515X, Q2417X, and K4022X, which previously were reported in Asian AD cohorts, were selected for FLG mutation analysis. We demonstrated that 15.7% of Koreans with AD in our study had four FLG null mutations: S2889X, S3296X, 3321delA, and K4022X. 3321delA (n=6, 9.1%) was the most common FLG mutation in our AD cohort followed by K4022X (n=3, 4.5%). This prevalence is similar to that in China; 3321delA is one of the most prevalent mutations in Chinese patients with AD.24 In a recent study, Park, et al.14 screened 81 Korean AD patients and K4022X was the most common. We also found that K4022X was the second most common mutation in our cohort; therefore, K4022X is thought to be a common mutation in Koreans with AD. There were differences of prevalent FLG mutations and AD-associated phenotype between the previously published two studies. Park, et al.14 reported new FLG mutations in Korean AD patients by analyzing coding exons, whereas we analyzed known mutations. The differences in FLG mutations and AD-associated phenotype may be the result of small sample size in both studies. S2889X (n=1, 1.5%) and S3296X (n=2, 3.1%), which are common in Japanese patients with AD, were also detected in two Koreans in our study. S2554X, which was the most common FLG mutation in Japan, was not detected in our study. One patient who had two mutations, S2889X and S3296X, had hyperlinear palms, clinical features of IV, and severe AD. Notably, this study was the first to detect the S2889X mutation in Koreans. This study expanded our understanding of the landscape of FLG-null mutations in Koreans with AD. The frequency of FLG mutation was 31.4% and 26.0% in Chinese patients with AD in previous reports.2324 A Japanese case–control study of eight FLG mutations demonstrated that about 27% of Japanese patients with AD carried at least one FLG mutation.22 The frequency of FLG mutations was 20.2% in Singaporean Chinese patients with AD or IV.26 In our study, the frequency of FLG mutations in Korean patients with AD (15.7%) was similar to that reported by Park, et al.14 The frequency of FLG mutations in Koreans with AD seems to be lower than that in other Asian countries. The low frequency of FLG mutations in our study can be explained by the fact that AD is a multifactorial disease that is affected by genetic and environmental factors. Mutations in other barrier-related genes may contribute to AD in our cohort. In addition, decreased FLG expression in AD as a result of genetic mutations or skin inflammation can induce acquired FLG deficiency. Barrier impairment in AD patients with severe inflammation has been reported to be similar in patients with wild-type and mutant FLG. These FLG alterations due to inflammation can also explain the low FLG mutation frequency in individuals with AD.527 The other important finding of our study is the association between FLG mutations and clinical features of AD in the Korean population. Palmar hyperlinearity and allergic sensitization with increased total IgE levels have been previously reported to be strongly associated with mutant FLG.2628 A significant association between palmar hyperlinearity and FLG mutations was also observed in our study. Previously, associations between FLG mutations and AD severity have been reported.26 In contrast, other groups did not identify an association between FLG mutations and disease severity or skin barrier defects, characterized by high transepidermal water loss.212324 Although AD has been reported to be more severe in patients with FLG mutations, there were no significant associations between FLG mutations and AD severity in our study. The lack of association between FLG mutations and AD severity maybe due to the fact that the SCORAD is a momentary variable that does not reflect overall disease activity.29 Any associated between early-onset AD and FLG mutations is still controversial. FLG mutations are related to early onset and persistent AD.30 However, Meng, et al.31 did not find an association between early-onset AD and the FLG mutation 3321delA. Age of onset was also not significantly associated with FLG mutations in the present study. In conclusion, our study expands our understanding of the landscape of FLG mutations in Koreans by finding four FLG mutations, of which one has not previously been reported in Koreans with AD. We also found that the frequency of FLG mutations in Korean AD was lower than that of other Asian countries. The FLG mutation spectrum in our cohort was both distinct and partially overlapping with other Asian AD cohorts. We also demonstrated a significant association between FLG mutations and AD phenotype (elevated IgE, palmar hyperlinearity, and a family history of allergic disease).
  30 in total

1.  Prevalent and rare mutations in the gene encoding filaggrin in Japanese patients with ichthyosis vulgaris and atopic dermatitis.

Authors:  Toshifumi Nomura; Masashi Akiyama; Aileen Sandilands; Ikue Nemoto-Hasebe; Kaori Sakai; Akari Nagasaki; Colin N A Palmer; Frances J D Smith; W H Irwin McLean; Hiroshi Shimizu
Journal:  J Invest Dermatol       Date:  2008-11-27       Impact factor: 8.551

2.  Analysis of MAST-CLA Results as a Diagnostic Tool in Allergic Skin Diseases.

Authors:  Jung Won Shin; Seon-Pil Jin; Jong Hee Lee; Soyun Cho
Journal:  Ann Dermatol       Date:  2010-02-28       Impact factor: 1.444

3.  Wide spectrum of filaggrin-null mutations in atopic dermatitis highlights differences between Singaporean Chinese and European populations.

Authors:  H Chen; J E A Common; R L Haines; A Balakrishnan; S J Brown; C S M Goh; H J Cordell; A Sandilands; L E Campbell; K Kroboth; A D Irvine; D L M Goh; M B Y Tang; H P van Bever; Y C Giam; W H I McLean; E B Lane
Journal:  Br J Dermatol       Date:  2011-07       Impact factor: 9.302

4.  Filaggrin loss-of-function mutations are not associated with atopic dermatitis that develops in late childhood or adulthood.

Authors:  H Rupnik; M Rijavec; P Korošec
Journal:  Br J Dermatol       Date:  2015-01-06       Impact factor: 9.302

5.  Filaggrin in the frontline: role in skin barrier function and disease.

Authors:  Aileen Sandilands; Calum Sutherland; Alan D Irvine; W H Irwin McLean
Journal:  J Cell Sci       Date:  2009-05-01       Impact factor: 5.285

6.  Filaggrin null mutations are associated with atopic dermatitis and elevated levels of IgE in the Japanese population: a family and case-control study.

Authors:  Hisako Enomoto; Kenji Hirata; Kenta Otsuka; Toshiharu Kawai; Takenori Takahashi; Tomomitsu Hirota; Yoichi Suzuki; Mayumi Tamari; Fujio Otsuka; Shigeharu Fujieda; Tadao Arinami; Emiko Noguchi
Journal:  J Hum Genet       Date:  2008-06-03       Impact factor: 3.172

Review 7.  Ichthyosis vulgaris: the filaggrin mutation disease.

Authors:  J P Thyssen; E Godoy-Gijon; P M Elias
Journal:  Br J Dermatol       Date:  2013-05-06       Impact factor: 9.302

8.  A new filaggrin gene mutation in a Korean patient with ichthyosis vulgaris.

Authors:  Yuka Ohguchi; Toshifumi Nomura; Shotaro Suzuki; Osamu Mizuno; Yukiko Nomura; Ikue Nemoto-Hasebe; Hiroyuki Okamoto; Aileen Sandilands; Masashi Akiyama; W H Irwin Mclean; Hiroshi Shimizu
Journal:  Eur J Dermatol       Date:  2014 Jul-Aug       Impact factor: 3.328

9.  Filaggrin gene mutation c.3321delA is associated with various clinical features of atopic dermatitis in the Chinese Han population.

Authors:  Li Meng; Li Wang; Huayang Tang; Xianfa Tang; Xiaoyun Jiang; Jinhua Zhao; Jing Gao; Bing Li; Xuhui Fu; Yan Chen; Weiyi Yao; Wenying Zhan; Bo Wu; Dawei Duan; Changbing Shen; Hui Cheng; Xianbo Zuo; Sen Yang; Liangdan Sun; Xuejun Zhang
Journal:  PLoS One       Date:  2014-05-23       Impact factor: 3.240

10.  Loss-of-function mutations in the gene encoding filaggrin cause ichthyosis vulgaris.

Authors:  Frances J D Smith; Alan D Irvine; Ana Terron-Kwiatkowski; Aileen Sandilands; Linda E Campbell; Yiwei Zhao; Haihui Liao; Alan T Evans; David R Goudie; Sue Lewis-Jones; Gehan Arseculeratne; Colin S Munro; Ann Sergeant; Gráinne O'Regan; Sherri J Bale; John G Compton; John J DiGiovanna; Richard B Presland; Philip Fleckman; W H Irwin McLean
Journal:  Nat Genet       Date:  2006-01-29       Impact factor: 38.330

View more
  8 in total

1.  Dietary Diversity during Early Infancy Increases Microbial Diversity and Prevents Egg Allergy in High-Risk Infants.

Authors:  Bo Ra Lee; Hye-In Jung; Su Kyung Kim; Mijeong Kwon; Hyunmi Kim; Minyoung Jung; Yechan Kyung; Byung Eui Kim; Suk-Joo Choi; Soo-Young Oh; Sun-Young Baek; Seonwoo Kim; Jaewoong Bae; Kangmo Ahn; Jihyun Kim
Journal:  Immune Netw       Date:  2021-11-12       Impact factor: 5.851

2.  Genetics and Epigenetics of Atopic Dermatitis: An Updated Systematic Review.

Authors:  Maria J Martin; Miguel Estravís; Asunción García-Sánchez; Ignacio Dávila; María Isidoro-García; Catalina Sanz
Journal:  Genes (Basel)       Date:  2020-04-18       Impact factor: 4.096

3.  Spontaneous atopic dermatitis in mice with a defective skin barrier is independent of ILC2 and mediated by IL-1β.

Authors:  Christian Schwartz; Tara Moran; Sean P Saunders; Agnieszka Kaszlikowska; Achilleas Floudas; Joana Bom; Gabriel Nunez; Yoichiro Iwakura; Luke O'Neill; Alan D Irvine; Andrew N J McKenzie; Graham Ogg; Patrick T Walsh; Jocelyne Demengeot; Padraic G Fallon
Journal:  Allergy       Date:  2019-04-29       Impact factor: 13.146

4.  Clinical Characteristics and Genetic Variations in Early-Onset Atopic Dermatitis Patients.

Authors:  Beom Jun Kim; Hye-Young Wang; Hyeyoung Lee; So-Yeon Lee; Soo-Jong Hong; Eung Ho Choi
Journal:  Ann Dermatol       Date:  2019-05-01       Impact factor: 1.444

Review 5.  Classifying atopic dermatitis: a systematic review of phenotypes and associated characteristics.

Authors:  A L Bosma; A Ascott; R Iskandar; K Farquhar; J Matthewman; M W Langendam; A Mulick; K Abuabara; H C Williams; P I Spuls; S M Langan; M A Middelkamp-Hup
Journal:  J Eur Acad Dermatol Venereol       Date:  2022-02-25       Impact factor: 9.228

Review 6.  Update on the Pathogenesis and Therapy of Atopic Dermatitis.

Authors:  Huaguo Li; Zhen Zhang; Hui Zhang; Yifeng Guo; Zhirong Yao
Journal:  Clin Rev Allergy Immunol       Date:  2021-08-02       Impact factor: 8.667

7.  FABP5 as a possible biomarker in atopic march: FABP5-induced Th17 polarization, both in mouse model and human samples.

Authors:  Jungsoo Lee; Bomi Kim; Howard Chu; KeLun Zhang; Hyeran Kim; Ji Hye Kim; Seo Hyeong Kim; Youdong Pan; Ji Yeon Noh; ZhengWang Sun; Jongsun Lee; Kyoung Yong Jeong; Kyung Hee Park; Jung-Won Park; Thomas S Kupper; Chang Ook Park; Kwang Hoon Lee
Journal:  EBioMedicine       Date:  2020-07-22       Impact factor: 11.205

Review 8.  Epidemiology, Diagnosis, and Treatment of Atopic Dermatitis in the Developing Countries of Asia, Africa, Latin America, and the Middle East: A Review.

Authors:  Yuri I Lopez Carrera; Anwar Al Hammadi; Yu-Huei Huang; Lyndon J Llamado; Ehab Mahgoub; Anna M Tallman
Journal:  Dermatol Ther (Heidelb)       Date:  2019-10-24
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.